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ABSTRACT
We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who 
received sunitinib or dose-escalated imatinib as second line.
All patients progressed on imatinib (400 mg/die) and received a second line 
treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 off or 
37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with 
clinical benefits.
64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 
94 patients. With a median follow-up of 61 months, median time to progression (TTP) 
in patients receiving sunitinib and imatinib was 10 (95% CI 9.7–10.9) and 5 months 
(95% CI 3.6–6.7) respectively (P = 0.012). No difference was found in overall 
survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated 
with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months 
P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370).
A second line with sunitinib was associated with an improved TTP in KIT exon 11 
mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed 
to be correlated with worse outcome in patients receiving imatinib-based second line.
INTRODUCTION
GIST account for 0.1–3% of gastrointestinal 
(GI) malignant tumours and represent the most 
common mesenchymal tumour of the GI tract (80%). 
Approximately 50% of GIST occur in the stomach, 30% 
are detected in the jejunum or ileum, 5% in the duodenum, 
5% in the rectum and less than 1% in the oesophagus [1].
About 85–95% of GIST harbour oncogenic mutations 
affecting KIT or PDGFRA, two highly homologues 
cell surface tyrosine kinase receptors for stem cells and 
platelet-derived growth factor. KIT is involved in more 
than 75–85% of cases: almost 85% of KIT mutations occur 
in the juxtamembrane domain (exon 11) and the 15% in 
the extracellular domain (exon 9) [2]. The majority of 
PDGFRA mutations affect the TK2 domain (exon 18) [3]. 
Since their identification as a separate entity in the late 
1990s, GIST were observed to be highly insensitive to 
standard chemotherapy and metastatic GIST were regarded 
as an incurable disease. As soon as GIST pathogenesis and 
progression was found to be driven by a KIT or PDGFRA 
mutations, they became the ideal solid tumour model for 
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tyrosine kinase inhibition therapies. The introduction 
of imatinib mesylate (Glivec®), a small-molecule 
tyrosine kinase inhibitor active against BCR-ABL, 
KIT, and PDGFR, changed dramatically the prognosis 
of unresectable or metastatic/advanced GIST patients, 
achieving a disease response in more than 50% of treated 
cases and stabilisation in almost 30%. On the basis of these 
encouraging results, imatinib was licensed in February 2002 
as a first line treatment for unresectable and/or metastatic 
GIST at the dose of 400 mg daily [4]. Subsequently, a large 
retrospective analysis from the MetaGIST group proved 
an advantage in progression-free survival (PFS) for KIT 
exon 9 mutated patients receiving imatinib 800 mg daily 
upfront, suggesting that a higher dose should be consider in 
this subgroup. Moreover, a dose escalation to 800 mg/day 
at the time of progression on first-line imatinib 400 mg/day 
was proven to be associated with new disease stabilisation 
in almost 30% of cases [5]. Sunitinib malate (Sutent®) is 
an oral multitargeted receptor tyrosine kinase inhibitor 
with selectivity for KIT and PDGFRA (and for PDGFRB, 
all three isoforms of vascular endothelial growth factor 
receptor, FMS-like tyrosine kinase 3, colony-stimulating 
factor 1 receptor and glial cell line-derived neurotrophic 
factor receptor) [6], whose administration is associated 
with a significant improvement in PFS (27.6 vs 6.4 weeks 
with placebo, P < 0.0001) for metastatic GIST patients 
progressing on imatinib. In 2006, FDA granted approval 
for sunitinib malate for the treatment of GIST after disease 
progression on (or intolerance to) imatinib, at the dose of 
50 mg, 4 weeks on and 2 weeks off treatment [7]. The 
continuous daily dosing of sunitinib at 37.5 daily is an 
active alternative dosing strategy with favourable safety [8].
In GIST patients progressing on sunitinib, 
regorafenib can provide a significant improvement 
in PFS compared with placebo. Based on the results 
from a randomized, phase III study, in July 2013 FDA 
approved oral regoarefenib (Stivarga ®) as a third line 
treatment [9].
Up today the best choice in second line is still 
unclear, being both imatinib dose escalation and sunitinib 
reasonable options. This is particularly true for KIT exon 
11 mutated patients, given their excellent response to 
400 mg in first line.
Aim of the present retrospective study is to compare 
the outcome of metastatic GIST patients harbouring KIT 
exon 11 mutations treated with sunitinib versus dose-
escalated imatinib after progression on imatinib 400 mg/die.
RESULTS
Patients population features
Patients characteristics are summarised in 
Table 1. Median age in our population was 58 years 
(range: 35–81). Sixty-eight (55%) patients were male 
and 55 (45%) were female.
One-hundred-two out of 123 subjects had an Eastern 
Cooperative Oncology Group (ECOG) performance score 
of 0 or 1.
The site of primary GIST was stomach in 71 patients 
(58%), small bowel in 31 (25%), colon or rectum in 21 
(17%), specifically 14 localized in the colon and 7 in 
the rectum. The primary tumour was unresected at the 
beginning of treatment course in 48 patients (39%) and 
71 (58%) showed liver involvement, Thirty nine patients 
(32%) had more than two metastatic organs involved 
(liver and local infiltration of other organs or peritoneal), 
43 (35%) patients showed peritoneal involvement.
The specific subtype of KIT exon 11 mutation was 
available for 94 (76%) patients: 42 (34%) harboured a KIT 
exon 11 deletion, while in 52 patients (66%) different exon 
11 genomic aberrations were detected.
Twenty-six (21%) patients received adjuvant 
imatinib after surgery, in 17 patients for the duration 
of one year, in the remaining 9 patients for three years. 
When progression occurs at the end of adjuvant treatment, 
all patient received imatinib 400 mg daily as firs line 
treatment.
The median duration of imatinib fist line therapy 
was 31 months (95% CI: 6–69 months). After progression 
on imatinib, 79 patients (64%) received imatinib dose 
escalation, 44 (36%) sunitinib (28 patients were treated 
according to the schedule 50 mg 4 weeks on/2 weeks off; 
16 patients were treated with 37.5 mg/day continuous 
daily dosing). Patients who progressed with Imatinib 
dose escalation received sunitinib. Median follow-up 
was 61 months (95% CI: 6–124 months). No intolerant 
imatinib patients were included in this retrospective 
analysis. In our series patients reported the common 
toxicity described in literature both in two arms, no G3 e 
G4 CTCAE were reported.
Radiological response and survival
Clinical benefit from imatinib dose escalation 
was observed in 46 patients (58.2%) (95% exact CI, 
39.0–64.0), and among those, 15 patients (18.9%) 
achieved a partial radiological response.
In patients treated with sunitinib clinical benefit 
was observed in 29 of 44 patients (65.9; 95% exact CI, 
39–79.0), and in 14 (31.8%) an objective partial 
radiological response was achieved.
Considering clinical benefit rate and radiological 
response no statistical significant difference was detected 
in both treatment arms (respectively, P = 0.5194 and 
P = 0.1660) Table 2 .
The median time to progression (TTP) in the 
population treated with sunitinib as a second line treatment 
was 10 months (95% CI 9.7–10.9) compared with 5 months 
(95% CI 3.6–6.7) in those who received imatinib 800 mg 
(P = 0.012) [Figure 1a]. No significant difference was 
found in term of overall survival between patients treated 
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with sunitinib and those treated with imatinib (OS) (62 
versus 58 months respectively, P = 0.883) between the 
two groups of patients, since patients who progress after 
imatinb escalated dose were cross over to receive treatment 
with sunitinib. In addition, no difference was detectable 
between patients treated with continuous dose schedule 
of sunitinib in comparison with the alternate schedule 4 
weeks on/2 weeks off. More in details patients treated with 
the continuous dose showed a median TTP of 10.3 months 
(95% CI 9.6–11.0) vs 9.2 months (95% CI 9.0–10.2) of 
patients treated with the alternate schedule (P = 0.801); the 
same in terms of OS: patients treated with the continuous 
dose showed a median OS of 64.6 months (95% CI 48.8–
81.5) vs 60.4 months (95% CI 43.5–79.4) of patients treated 
with the alternate schedule (P = 0.764).
Clinical outcome according to the type of KIT 
exon 11 mutation and in relation to the  
second line
Overall, considering the entire population 
independently by the second line choice the specific type 
of exon 11 KIT mutation was demonstrated to represent a 
significant prognostic factor in our patients’ population.
Table 1: Patients characteristics
Number of patients % of patients
Gender (Male) 68 55%




PS1 (ECOG 0 -1) 102 82%
Primary tumor 
Stomach 71 57%
Small bowel 31 25%
Colon rectum 21 18%
Primary tumors not resected at 
diagnosis 48 39%
Liver involvement 71 58%
>2 disease sites 39 32%
Peritoneal involvement 43 35%
Adjuvant imatinib 26 21%
Second line with Sunitinib 44 36%
Second line with Sunitinib alterantive schedule 16 13%
Second line with Imatinib (800 mg) 79 64%
Gist with exon 11 mutation detected 94 76%
Deleted exon 11 42 34%
Other exon 11 mutation 52 66%
Imatinibintolerance 0
1)Performance status
Table 2: Clinical benefit rate according to treatment
Patients Clinical benefit rate Partial radiological response
Imatinib (dose escalation) 79 58.2% 18.9%
Sunitinib 44 65.9% 31.8%
P values 0.5194 0.1660
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In details, 11 KIT deletion compared with other exon 
11 KIT mutations was identified as a negative prognostic 
factor in our patients population only for OS (76.0 95% 
CI: 68.5–114.5- vs 53.0 -95%CI: 47.9–88.4- P = 0.016), 
while there was no significant impact on Progression 
free survival (PFS) (9.4 -95%CI: 7.5–11.1- vs 7.8 -95% 
CI: 6.9–10.3- P = 0.261). These results confirm data 
from Kontogianni et al. that consider kit exon 11 deletion 
especially in cod 557/558 as independent prognostic factor 
in primary localized GIST [10].
Presence of deletions in KIT exon 11 was 
found to be associated with a shorter TTP in patients 
receiving imatinib-based second line therapy (7- 95% 
CI 3.1–10.4- and 17 months -95%CI 9.8–23.5- (P = 0.02), 
respectively). A negative trend was also recorded in terms 
of OS (54 -95%CI 21.0- 73.3- vs 71 -95%CI 45.3- 82. 
8- months, (P = 0.063) respectively). Conversely, deletions 
in KIT exon 11 were not associated with a decrease activity 
of sunitinib in second line (TTP: 9 -95% CI 7.9–10.5- vs 
12 -95%CI 9.4–13.2- months, P = 0.6; OS: 51 -95%CI 
44.3–60.7- vs 54 -95%CI 47.8–64.3- months, P = 0.370). 
These results are summarized in Tables 3 and 4.
DISCUSSION
GIST are the most common mesenchymal 
neoplasm of the gastrointestinal tract (80%) and 
represents about 5% of all sarcomas. Molecular 
characteristics were misdiagnosed until 1988 when 
Hirota and colleagues demonstrated that almost all 
GIST expressed KIT by immunohistochemistry (IHC) 
and harboured activating KIT mutations [11]. Nowadays, 
GIST represents a paradigm for successful targeted 
treatment with tyrosine kinase inhibitors (TKIs) and 
imatinib is regarded as the 1st-line treatment of choice 
in the metastatic setting. It is widely demostrated that 
KIT and PDGFRA mutational status affect response to 
imatinib. Phase II and III imatinib trials in patients with 
advanced GIST reported higher partial response rates 
and longer overall survival in patients with mutations 
in KIT exon 11 compared to patients with a mutation in 
KIT exon 9 or no detectable mutations (GIST wild-type) 
[12] Furthermore, almost all patients who experience 
early disease progression on imatinib treatment (400 
mg/day) have mutations in KIT exon 9 or in PDGFRA, 
or are wild type for the known KIT and PDGFRA 
mutations [5]. However, patients with KIT exon 9 
mutations have been shown to better respond to the 
double dose of imatinib (800 mg/day), although a higher 
incidence of adverse events has been reported [13]. 
On the basis of phase III studies showing that patients 
with KIT exon 9 mutations may achieve longer PFS on 
higher-dose imatinib [14], guidelines support the use of 
imatinib 800 mg/day as the standard treatment of choice 
in this molecular subgroup. As far as these data among 
patients with GIST who experienced progression on 
1st-line imatinib 400 mg/day, clinical data suggest that 
2nd-line treatment with either imatinib 800 mg/day or 
sunitinib may be considered as subsequent treatment, 
and those who progress on 1st-line imatinib 800 mg/
day may be switched to sunitinib. The efficacy of 
imatinib 800 mg/day after disease progression has 
been investigated in two phase  III clinical trials where 
patients with disease progression on the once daily (400 
Figure 1: Survival results. a. time to progression in the population treated with sunitinib as second line treatment was 10 months (95% 
CI 9.7–10.9) compared with 5 months (95% CI 3.6–6.7) in those who received imatinib 800 mg (P = 0.012). b. overall survival in the 
sunitinib and imatinib arm (58 versus 62 months respectively, P = 0.883).
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mg/day) imatinib regimen were offered the option of 
crossover to the twice daily (800 mg/day) arm. Both 
these trials showed a significant benefit in terms of 
progression free survival (PFS) and overll response 
rate (ORR) in patients who cross-over from imatinib 
400 mg/day to imatinib 800 mg/day concluding that a 
cross-over to high-dose imatinib is feasible and safe in 
GIST patients who progress on low-dose therapy [13, 
14]. On the other hand sunitinib administered at 50 mg/
day in 6-week cycles comprising 4 weeks on treatment 
followed by 2 weeks off treatment (schedule 4/2) 
becomes a valid alternative after prior progression to 
imatinib 400 mg/ die. In a phase III double-blind trial, 
patients with an imatinib-resistant/-intollerant GIST 
were randomized 2: 1 to receive sunitinib 50 mg/day 
on schedule 4/2 or placebo with cross- over from the 
placebo group to the sunitinib arm. The trials showed 
a benefit in terms of PFS and TTP in the sunitinib arm 
versus the placebo group [7].
Nowadays, in case of disease progression under 
imatinib 400 mg/die as adjuvant setting or as first-line 
therapy, the choice of a suitable second line therapy is 
still a matter of debate in clinical practice, since no data 
that compare imatinib 800 mg/die vs sunitinib as second 
line treatment are available. Moreover, considering only 
the KIT exon 11 mutated patients, who are the most 
sensitive to imatinib 400 mg, when a progression occurs, 
no data are available to support the use of imatinib 
800 mg/die as second line treatment in comparison 
with sunitinib [15]. A systematic review analysing the 
effectiveness of Imatinib escalating dose versus Sunitinb 
in patients who progressed after firs t line 400 mg/daliy 
Imatinb was conducted by Hislpo. The authors concluded 
that the statistical likelihood of response on both treatment 
may depend on exon mutational status encouraging further 
clinical randomized trials [16].
To our knowledge, this is the first retrospective 
analysis comparing the outcome of metastatic/advanced 
KIT exon 11 mutated GIST patients treated with sunitinib 
or dose-escalated imatinib as second line treatment. The 
aim of this study has been to identify which subgroup of 
metastatic KIT exon 11 mutated GIST patient could benefit 
of sunitinib rather than imatinb in order to better tailor 
the best therapeutic choice after the first line progression 
on the basis of molecular status. Moreover patients were 
stratified according to the type of KIT exon 11 mutation 
(deletions versus others) in order to verify if could be a 
different response to the two TKIs .
Our data showed that patients harbouring exon 
11 deletions present a worse outcome in terms of OS in 
both treatment arms comparing patients with other exon 
11 mutation; highlighting a possible negative prognostic 
role of deletion in this patients subset.
Furhermore the results of the study showed that 
there is an advantage in term of TTP in patients treated 
with sunitinib in comparison with patients in the imatinib 
arm, even if no difference in term of overall survival was 
found, since that OS is affected by all treatment history 
of each patients and by the biological background in part 
still unknown.
Interestingly, we showed that imatinib was less 
effective in the subgroup of patients harbouring a KIT 
exon 11 deletion than in those harbouring other kind of 
mutation in exon 11 in term of TTP, while no difference 
was found in patients treated with sunitinib. The present 
result is apparently in contrast with the data of the phase 
III trial that compared sunitinib to placebo as second 
line treatment in patients progressing after imatinib. 
Although a clinical benefit of sunitinib treatment 
was observed in all major mutant types, the primary 
response rate was significantly higher for KIT exon 9 
mutants than KIT 11 ones, suggesting a possible role of 
Table 4: Overall survival (months) according to type of exon 11 mutations and second-line treatment
Type of Exon 11 mutation Imatinib Overall survival (months) Sunitinb Overall Survival (months)
Exon 11 deletions 54 months 51 months
Exon 11 other mutations 71 months 58 months
P values (Overall survival) 0.063 0.370
Table 3: Time to progression (months) according to type of exon 11 mutations and second-line 
treatment
Type of Exon 11 mutation Imatinib Time to progression (months) SunItinib Time to progression (months)
Exon-11 deletions 7 months 9 months
Exon-11 other mutations 17 months 12 months
P-Values (Time to 
progression) 0.02 0.683
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primary and secondary mutations on sunitinib activity 
[7]. In fact, the impact of primary and secondary kinase 
genotype on sunitinib activity was evaluated in different 
studied confirming that patient with primary mutations 
on KIT exon 9 had a longer PFS and OS than patient 
with KIT exon 11 mutations, while a better response was 
found in KIT exon 11 mutated patients with secondary 
mutations on exons 13 and 14 than in patients with 
secondary mutations on exons 17 and 18 [17, 18] [19]. 
These data were also confirmed in vitro study where 
GIST cell with primary exon 11 mutation who secondary 
acquired a KIT exon 13 mutation were more sensitive 
to sunitinib than imatinib [18]. According to these 
data, we can hypothesize that the KIT exon 11 mutated 
patients in our series, who better responded in term of 
TTP in the sunitinib arm may harbor a second acquired 
mutation in the exons that are particularly sensitive to 
sunitinib such as 13 on 14 exons, even of molecular data 
on secondary mutations are not available, since both 
Italian and European guidelines do not advise the use 
secondary biopsy at imatinib progression. Futhermore 
considering data from literature we can hypotyze that 
exon deletion on kit-11 in our series ,presents a worse 
prognosis respect to not deleted GIST , confirming data 
from previous study that reported exon 11 mutation 
especially in resected gastric GIST as independent 
factors of worse prognosis [20, 10]. Furthermore we 
can suppose that these subset of patients may acquire 
secondary mutation resistant to imatinib escalated 
dose than to sunitiib as reported in our results in terms 
of TTP.
However, as is well known, several molecular 
mechanisms underlying secondary resistance in GIST 
have been described and in many cases the secondary 
resistance may not sustained by the acquisition of novel 
mutations [21]. Therefore, the different efficacy of 
sunitinib and of imatinib dose escalation in KIT mutated 
GIST patients as second line treatment, could be sustained 
by other molecular mechanisms still unknown.
In conclusion, to our knowledge, this is the first 
retrospective report on the comparison between imatinib 
800 mg and sunitinib as second line treatment in KIT exon 
11 mutated GIST patients. On the basis of our preliminary 
results, sunitinib as second line treatment may be mostly 
considered in patients with KIT exon 11 deletion after 
failure to imatinib. However, the clinical value of this 
analysis should be validated in prospective studies on 
larger series of patients, in order to tailor the choice of 
second line treatment according to the molecular data. 
Moreover, the repetition of the mutational analysis with 
new diagnostic tool such liquid biopsy [22], if feasible, 
after disease progression, may be recommended in order 
to identify secondary mutations or other alterations and 




One-hundred-twenty-three consecutive metastatic 
or advanced GIST patients treated at four referring Italian 
institutions (University Campus Bio-Medico, Rome; 
Sant’Orsola Malpighi Hospital, Bologna; Istituto Nazionale 
Tumori, Milan; Policlinico P. Giaccone, Palemo) were 
included in the present retrospective analysis. All the patients 
included harboured a KIT exon 11 mutation and progressed 
after a first line with imatinib 400 mg/die. Up on physician 
choice, they all receive either imatinib dose escalation 
(800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 weeks 
off or 37.5 mg/die continuous daily dosing) as second line 
treatment. There were no difference in terms of age , gender 
and second line treatment causes between two arms even 
if it was a retrospective analysis. KIT mutational analysisis 
was made at the diagnosis. In patient with Gist resected at 
primary diagnosis the mutational status was detected on the 
primary site. All the analysis was made with polymerase 
chain reaction (PCR) amplification of genomic DNA.
Methods used for the analysis were carried out 
in accordance with the approved guidelines, and the 
institutional approval committee of Campus Bio-Medico 
of Rome approved the experimental protocol.
Data collection
A database including details on patient’s 
demographic characteristics (age, gender), disease 
(site of the primary, presence of the primary, peritoneal 
involvement liver involvement and type of KIT exon 11 
mutation), treatment (imatinib dose escalation or sunitinib), 
response to the treatment and outcome was shared among 
the contributing centres and data were retrospectively 
collected. Response to treatment defined as Clinical 
Benefit Rate (percentage of patients who have achieved 
complete response, partial response and stable disease) was 
evaluated according to RECIST 1.1 criteria or according to 
Choi criteria (on the basis of physicians’ experience), since 
this was a retrospective analysis no central radiological 
review was made.
Statistical analysis
Descriptive analysis was made using median values 
and range. Differences between groups were assessed 
using the Chi-squared test. Time to progression (TTP) was 
calculated as the period from the treatment start to the first 
evidence of disease progression. Overall survival (OS) 
was calculated from the time of diagnosis of metastatic 
GIST to the time of death or the last documented time the 
patient was known to be alive. Patients with no evidence 
of progression were censored at the last tumor assessment. 
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Death was considered an event regardless of the cause. 
Patients alive or lost to follow-up were censored at the last 
contact. Survival analysis was performed by Kaplan-Meier 
product-limit method and the differences in term of TTP 
and OS according to the treatment received or the type 
of mutation detected were evaluated by the log-rank test. 
SPSS software (version 17.00, SPSS, Chicago, ILQ5) was 
used for statistical analysis. A P value of less than 0.05 
was considered to indicate statistical significance.
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